GlassScriptPhysician profile
Paloma A Becker
NPI 1114441177
$7,148.49
in general payments reported to CMS, 2019-2025
34 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $764 · 2023: $1,913 · 2024: $1,747 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,801 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,801.13 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,533.58 | 2021-2024 | Axonics |
| Sumitomo Pharma America, INC. | $1,008.35 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $824.93 | 2021-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $567.55 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Calyxo, INC. | $405.22 | 2023-2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $275.66 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Dendreon Pharmaceuticals LLC | $274.16 | 2024-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $253.64 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.11 | 2023-2025 | |
| Abbvie INC. | $208.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $198.07 | 2022-2025 | Lynparza |
| Progenics Pharmaceuticals, INC. | $170.32 | 2022-2025 | |
| Antares Pharma, INC. | $148.13 | 2022 | |
| Procept Biorobotics Corporation | $99.40 | 2022 | |
| Tolmar, INC. | $93.37 | 2023-2025 | Eligard, Jatenzo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $90.95 | 2022-2025 | |
| Verity Pharmaceuticals INC. | $85.55 | 2023-2025 | Trelstar |
| Alnylam Pharmaceuticals INC. | $77.52 | 2021-2022 | |
| Boston Scientific Corporation | $76.49 | 2022-2024 | Rezum Generator |
| Urogen Pharma, INC. | $67.60 | 2024-2025 | |
| Urovant Sciences INC | $65.75 | 2021-2022 | |
| Pfizer INC. | $64.54 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $48.08 | 2024 | Adstiladrin |
| Medtronic, INC. | $41.69 | 2024-2025 | Interstim |
| Siemens Medical Solutions USA, INC. | $37.39 | 2023 | Biograph Horizon-3r |
| Ambu INC. | $34.21 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $33.85 | 2024 | |
| Foundation Medicine, INC. | $33.48 | 2023 | |
| Beone Medicines USA, INC. | $30.64 | 2025 | Tevimbra |
| Immunitybio, INC. | $25.88 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $18.97 | 2022 | |
| Angiodynamics, INC. | $13.85 | 2025 | Nanoknife |
| Endo USA, INC. | $13.55 | 2024 | Xiaflex |
| Genzyme Corporation | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paloma Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.